Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Open Access

Correction

Correction: Effects of KRAS, STK11, KEAP1, and TP53 mutations on the clinical outcomes of immune checkpoint inhibitors among patients with lung adenocarcinoma

  • Yao Liang,
  • Osamu Maeda,
  • Chiaki Kondo,
  • Kazuki Nishida,
  • Yuichi Ando

There are errors in the author affiliations. The correct affiliations are as follows:

Yao Liang1, Osamu Maeda2, Chiaki Kondo2, Kazuki Nishida3, Yuichi Ando2

1 Division of Clinical Oncology and Chemotherapy, Department of Integrated Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan, 2 Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Aichi, Japan, 3 Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Aichi, Japan

Reference

  1. 1. Liang Y, Maeda O, Kondo C, Nishida K, Ando Y. Effects of KRAS, STK11, KEAP1, and TP53 mutations on the clinical outcomes of immune checkpoint inhibitors among patients with lung adenocarcinoma. PLoS One. 2024;19(7):e0307580. pmid:39037971

Citation: Liang Y, Maeda O, Kondo C, Nishida K, Ando Y (2025) Correction: Effects of KRAS, STK11, KEAP1, and TP53 mutations on the clinical outcomes of immune checkpoint inhibitors among patients with lung adenocarcinoma. PLoS One 20(8): e0330099. https://doi.org/10.1371/journal.pone.0330099

Published: August 11, 2025

Copyright: © 2025 Liang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.